Development

In early 2022, TeesuVac obtained US market clearance for its first biopsy gun intended for ultrasound-guided breast biopsy.

In the second half of 2022, TeesuVac started developing a biopsy device with vacuum-assisted, multiple-specimen collection technology.

The initial design strongly emphasizes clinical user experience. The strict stage-gate development method ensures that all inputs are considered, resulting in a device with excellent handling characteristics that aids in breast biopsy procedures.

The TeesuVac biopsy device platform comprises five patents.

The team’s core engineering competence is built on many years of experience within the field, and new skills are incorporated into the team as needed.